Abstract
Background This paper describes the methods and conceptual framework for Wave 1 of the Population Assessment of Tobacco and Health (PATH) Study data collection. The National Institutes of Health, through the National Institute on Drug Abuse, is partnering with the Food and Drug Administration’s (FDA) Center for Tobacco Products to conduct the PATH Study under a contract with Westat. Methods The PATH Study is a nationally representative, longitudinal cohort study of 45 971 adults and youth in the USA, aged 12 years and older. Wave 1 was conducted from 12 September 2013 to 15 December 2014 using Audio Computer-Assisted Self-Interviewing to collect information on tobacco-use patterns, risk perceptions and attitudes towards current and newly emerging tobacco products, tobacco initiation, cessation, relapse behaviours and health outcomes. The PATH Study’s design allows for the longitudinal assessment of patterns of use of a spectrum of tobacco products, including initiation, cessation, relapse and transitions between products, as well as factors associated with use patterns. Additionally, the PATH Study collects biospecimens from consenting adults aged 18 years and older and measures biomarkers of exposure and potential harm related to tobacco use. Conclusions The cumulative, population-based data generated over time by the PATH Study will contribute to the evidence base to inform FDA’s regulatory mission under the Family Smoking Prevention and Tobacco Control Act and efforts to reduce the Nation’s burden of tobacco-related death and disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 371-378 |
| Number of pages | 8 |
| Journal | Tobacco Control |
| Volume | 26 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jul 1 2017 |
Fingerprint
ASJC Scopus subject areas
- Health(social science)
- Public Health, Environmental and Occupational Health
Cite this
Design and methods of the Population Assessment of Tobacco and Health (PATH) Study. / Hyland, Andrew; Ambrose, Bridget K.; Conway, Kevin P.; Borek, Nicolette; Lambert, Elizabeth; Carusi, Charles; Taylor, Kristie; Crosse, Scott; Fong, Geoffrey T.; Michael Cummings, K.; Abrams, David; Pierce, John P.; Sargent, James; Messer, Karen; Bansal-Travers, Maansi; Niaura, Raymond; Vallone, Donna; Hammond, David; Hilmi, Nahla; Kwan, Jonathan; Piesse, Andrea; Kalton, Graham; Lohr, Sharon; Pharris-Ciurej, Nick; Castleman, Victoria; Green, Victoria R.; Tessman, Greta; Kaufman, Annette; Lawrence, Charles; Van Bemmel, Dana M.; Kimmel, Heather L.; Blount, Ben; Yang, Ling; O’Brien, Barbara; Tworek, Cindy; Alberding, Derek; Hull, Lynn C.; Cheng, Yu Ching; Maklan, David; Backinger, Cathy L.; Compton, Wilson M.
In: Tobacco Control, Vol. 26, No. 4, 01.07.2017, p. 371-378.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Design and methods of the Population Assessment of Tobacco and Health (PATH) Study
AU - Hyland, Andrew
AU - Ambrose, Bridget K.
AU - Conway, Kevin P.
AU - Borek, Nicolette
AU - Lambert, Elizabeth
AU - Carusi, Charles
AU - Taylor, Kristie
AU - Crosse, Scott
AU - Fong, Geoffrey T.
AU - Michael Cummings, K.
AU - Abrams, David
AU - Pierce, John P.
AU - Sargent, James
AU - Messer, Karen
AU - Bansal-Travers, Maansi
AU - Niaura, Raymond
AU - Vallone, Donna
AU - Hammond, David
AU - Hilmi, Nahla
AU - Kwan, Jonathan
AU - Piesse, Andrea
AU - Kalton, Graham
AU - Lohr, Sharon
AU - Pharris-Ciurej, Nick
AU - Castleman, Victoria
AU - Green, Victoria R.
AU - Tessman, Greta
AU - Kaufman, Annette
AU - Lawrence, Charles
AU - Van Bemmel, Dana M.
AU - Kimmel, Heather L.
AU - Blount, Ben
AU - Yang, Ling
AU - O’Brien, Barbara
AU - Tworek, Cindy
AU - Alberding, Derek
AU - Hull, Lynn C.
AU - Cheng, Yu Ching
AU - Maklan, David
AU - Backinger, Cathy L.
AU - Compton, Wilson M.
PY - 2017/7/1
Y1 - 2017/7/1
N2 - Background This paper describes the methods and conceptual framework for Wave 1 of the Population Assessment of Tobacco and Health (PATH) Study data collection. The National Institutes of Health, through the National Institute on Drug Abuse, is partnering with the Food and Drug Administration’s (FDA) Center for Tobacco Products to conduct the PATH Study under a contract with Westat. Methods The PATH Study is a nationally representative, longitudinal cohort study of 45 971 adults and youth in the USA, aged 12 years and older. Wave 1 was conducted from 12 September 2013 to 15 December 2014 using Audio Computer-Assisted Self-Interviewing to collect information on tobacco-use patterns, risk perceptions and attitudes towards current and newly emerging tobacco products, tobacco initiation, cessation, relapse behaviours and health outcomes. The PATH Study’s design allows for the longitudinal assessment of patterns of use of a spectrum of tobacco products, including initiation, cessation, relapse and transitions between products, as well as factors associated with use patterns. Additionally, the PATH Study collects biospecimens from consenting adults aged 18 years and older and measures biomarkers of exposure and potential harm related to tobacco use. Conclusions The cumulative, population-based data generated over time by the PATH Study will contribute to the evidence base to inform FDA’s regulatory mission under the Family Smoking Prevention and Tobacco Control Act and efforts to reduce the Nation’s burden of tobacco-related death and disease.
AB - Background This paper describes the methods and conceptual framework for Wave 1 of the Population Assessment of Tobacco and Health (PATH) Study data collection. The National Institutes of Health, through the National Institute on Drug Abuse, is partnering with the Food and Drug Administration’s (FDA) Center for Tobacco Products to conduct the PATH Study under a contract with Westat. Methods The PATH Study is a nationally representative, longitudinal cohort study of 45 971 adults and youth in the USA, aged 12 years and older. Wave 1 was conducted from 12 September 2013 to 15 December 2014 using Audio Computer-Assisted Self-Interviewing to collect information on tobacco-use patterns, risk perceptions and attitudes towards current and newly emerging tobacco products, tobacco initiation, cessation, relapse behaviours and health outcomes. The PATH Study’s design allows for the longitudinal assessment of patterns of use of a spectrum of tobacco products, including initiation, cessation, relapse and transitions between products, as well as factors associated with use patterns. Additionally, the PATH Study collects biospecimens from consenting adults aged 18 years and older and measures biomarkers of exposure and potential harm related to tobacco use. Conclusions The cumulative, population-based data generated over time by the PATH Study will contribute to the evidence base to inform FDA’s regulatory mission under the Family Smoking Prevention and Tobacco Control Act and efforts to reduce the Nation’s burden of tobacco-related death and disease.
UR - http://www.scopus.com/inward/record.url?scp=85021840121&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021840121&partnerID=8YFLogxK
U2 - 10.1136/tobaccocontrol-2016-052934
DO - 10.1136/tobaccocontrol-2016-052934
M3 - Article
VL - 26
SP - 371
EP - 378
JO - Tobacco Control
JF - Tobacco Control
SN - 0964-4563
IS - 4
ER -